1. A Neglected Case of Multifocal Liposarcoma Presented in Five Different Sites in a Syrian Woman: A case report. (2019) Authors: Alawad, Ieman; Al-Haj, Ahmad; Ghazal, Ahmad; Ibrahim, Amna; Masri, Ruqaya Journal: International journal of surgery case reports Issue: Volume 65(2019) Page Start: 262 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis. Issue 2 (February 2020) Authors: Gao, Jennifer J; Cheng, Joyce; Bloomquist, Erik; Sanchez, Jacquelyn; Wedam, Suparna B; Singh, Harpreet; Amiri-Kordestani, Laleh; Ibrahim, Amna; Sridhara, Rajeshwari; Goldberg, Kirsten B; Theoret, Marc R; Kluetz, Paul G; Blumenthal, Gideon M; Pazdur, Richard; Beaver, Julia A; Prowell, Tatiana M Journal: Lancet oncology Issue: Volume 21:Issue 2(2020) Page Start: 250 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin‐Containing Chemotherapy. (12th December 2018) Authors: Suzman, Daniel L.; Agrawal, Sundeep; Ning, Yang‐min; Maher, V. Ellen; Fernandes, Laura L.; Karuri, Stella; Tang, Shenghui; Sridhara, Rajeshwari; Schroeder, Jason; Goldberg, Kirsten B.; Ibrahim, Amna; McKee, Amy E.; Pazdur, Richard; Beaver, Julia A. Journal: Oncologist Issue: Volume 24:Number 4(2019) Page Start: 563 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. FDA Approval Summary: Nivolumab in Advanced Renal Cell Carcinoma After Anti‐Angiogenic Therapy and Exploratory Predictive Biomarker Analysis. (23rd February 2017) Authors: Xu, James Xunhai; Maher, V. Ellen; Zhang, Lijun; Tang, Shenghui; Sridhara, Rajeshwari; Ibrahim, Amna; Kim, Geoffrey; Pazdur, Richard Journal: Oncologist Issue: Volume 22:Number 3(2017) Page Start: 311 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. FDA Approval Summary: Nivolumab in Advanced Renal Cell Carcinoma After Anti‐Angiogenic Therapy and Exploratory Predictive Biomarker Analysis. (March 2017) Authors: Xu, James Xunhai; Maher, V. Ellen; Zhang, Lijun; Tang, Shenghui; Sridhara, Rajeshwari; Ibrahim, Amna; Kim, Geoffrey; Pazdur, Richard Journal: Oncologist Issue: Volume 22:Number 3(2017) Page Start: 311 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious BRCA‐Mutated Metastatic Castrate‐Resistant Prostate Cancer. (17th November 2020) Authors: Anscher, Mitchell S.; Chang, Elaine; Gao, Xin; Gong, Yutao; Weinstock, Chana; Bloomquist, Erik; Adeniyi, Oluseyi; Charlab, Rosane; Zimmerman, Sarah; Serlemitsos‐Day, Maritsa; Ning, Yang Min; Mayrosh, Ruth; Fuller, Barbara; Trentacosti, Ann Marie; Gallagher, Pamela; Bijwaard, Karen; Philip, Reena;... Journal: Oncologist Issue: Volume 26:Number 2(2021) Page Start: 139 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Survival outcomes in older men with non-metastatic castration-resistant prostate cancer treated with androgen receptor inhibitors: a US Food and Drug Administration pooled analysis of patient-level data from three randomised trials. Issue 9 (September 2021) Authors: Fallah, Jaleh; Zhang, Lijun; Amatya, Anup; Gong, Yutao; King-Kallimanis, Bellinda; Bhatnagar, Vishal; Weinstock, Chana; Suzman, Daniel L; Agrawal, Sundeep; Chang, Elaine; Anscher, Mitchell S; Chi, Dow-Chung; Xu, James X; Brewer, Jamie R; Brave, Michael H; Hadadi, Mehrnoosh; Theoret, Marc R; Kluet... Journal: Lancet oncology Issue: Volume 22:Issue 9(2021) Page Start: 1230 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. U.S. Food and Drug Administration Approval Summary: Enzalutamide for the Treatment of Patients With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer. (12th June 2015) Authors: Ning, Yang-Min; Brave, Michael; Maher, V. Ellen; Zhang, Lijun; Tang, Shenghui; Sridhara, Rajeshwari; Kim, Geoffrey; Ibrahim, Amna; Pazdur, Richard Journal: Oncologist Issue: Volume 20:Number 8(2015) Page Start: 960 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. U.S. Food and Drug Administration Approval Summary: Enzalutamide for the Treatment of Patients With Chemotherapy‐Naïve Metastatic Castration‐Resistant Prostate Cancer. (12th June 2015) Authors: Ning, Yang‐Min; Brave, Michael; Maher, V. Ellen; Zhang, Lijun; Tang, Shenghui; Sridhara, Rajeshwari; Kim, Geoffrey; Ibrahim, Amna; Pazdur, Richard Journal: Oncologist Issue: Volume 20:Number 8(2015) Page Start: 960 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗